Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Premier Carton (Oxali 100mg Premier Carton)
Oxaliplatin Injection, Solution
Product Images NDC 71288-172
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 71288-172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel – Oxaliplatin Injection, Usp 100 mg Premier Vial Label (Oxali 100mg Premier Vial)
Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Premier Carton (Oxali 50mg Premier Carton)
This text appears to be a description of a medication called Oxaliplatin Injection, USP, used for intravenous purposes. The medication comes in a sterile aqueous solution and must be diluted with 5% dextrose injection before use. It contains 50mg per 10mL, with caution that it is a cytotoxic agent. The dosage and administration instructions are provided on the package, and it is recommended to store the medication at 25°C. The medication is presented in single-dose vials and should not be diluted with sodium-containing solutions. For questions or inquiries, a contact number is provided. The packaging is designed by PREMIERProRx and is labeled as nonpyrogenic.*
Principal Display Panel – Oxaliplatin Injection, Usp 50 mg Premier Vial Label (Oxali 50mg Premier Vial)
This text appears to be a product label that includes information about a medical product. The label mentions characteristics like "10 mL Single-Dose Vial," "50 mg per 10 mL," "For Intravenous Use Only," and the name of the drug "Oxaliplat." It also provides the NDC number for the injection. The format suggests that this is a detailed label or packaging information for a medical product.*
Figure 1 (Oxali Premier Fig 1)
Figure 2 (Oxali Premier Fig 2)
This text appears to be from a medical document related to DFS (Disease-Free Survival) probability calculation for patients receiving different treatment arms. It lists various stages, test names, and time periods related to the disease-free survival of the patients. The treatment arms mentioned are FOLFOX4 and DUKES C, and the document may be part of a clinical study or trial.*
Figure 3 (Oxali Premier Fig 3)
Structure (Oxali Premier Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
